



DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE
NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: <http://grants.nih.gov/grants/olaw/olaw.htm>

FOR EXPRESS MAIL:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 480-3387

January 18, 2022

Re: Animal Welfare Assurance
A3368-01 [OLAW Case 11X]

Dr. Nadine Connor
Associate Vice Chancellor
for Research Policy and Compliance
University of Wisconsin-Madison
(b) (4) Bascom Hall – 500 Lincoln Drive
Madison, WI 53706

Dear Dr. Connor,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your January 4, 2022 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at the University of Wisconsin – Madison's Wisconsin National Primate Research Center. Your letter supplemented the information in the preliminary telephone report on December 22, 2021. According to the information provided, OLAW understands that two macaques were treated with an antibiotic for experimental reasons as suggested and monitored by a veterinarian. This antibiotic treatment was not indicated in the protocol. There were no adverse consequences associated with this treatment. The animals involved were supported by PHS funds.

The protocol has since been amended to allow for this treatment option. The technicians involved in this incident have undergone retraining stressing the importance of reading the protocol and being aware of all substances being administered and the purpose for each substance administered. This incident was further discussed with all technicians in the involved group at a regular team meeting. The veterinarian that suggested the antibiotic treatment underwent retraining stressing the importance of making sure that all substances administered to live animals are in the protocol, or if they are not, that the PI must request and have approved an amendment to the protocol to include the new substance prior to its administration.

The consideration of this unfortunate incident by the University of Wisconsin - Madison was consistent with the philosophy of institutional self-regulation. Similarly, the actions taken to address the issue and prevent recurrence were appropriate. Please ensure that no costs associated with the unapproved treatment are charged to the grant or contract. We appreciate being informed of this matter and find no cause for further action by this office.

Sincerely,

Brent C. Morse -S

Digitally signed by Brent C.
Morse -S
Date: 2022.01.18 07:47:14 -05'00'

Brent C. Morse, DVM
Director
Division of Compliance Oversight
Office of Laboratory Animal Welfare

cc: IACUC contact
Dr. Robert M. Gibbens, USDA, APHIS, AC



A3368-11X

January 4, 2022

Dr. Brent Morse, DVM, DAACLAM
Director, Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health
RKL1, Suite 360, MSC 7982
6705 Rockledge Drive
Bethesda, MD 20892-7892

Dear Dr. Morse:

The University of Wisconsin-Madison, in accordance with Assurance A3368-01 and PHS Policy IV.F.3, provides this report of an incident first reported to you via telephone by [REDACTED] (b) (6) on December 10, 2021.

In this incident, two macaques were treated with an antibiotic for experimental reasons as suggested and monitored by a veterinarian. This antibiotic treatment was not indicated in the protocol. The protocol has since been amended to allow for this treatment option. The technicians involved in this incident have undergone retraining stressing the importance of reading the protocol and being aware of all substances being administered and the purpose for each substance administered. This incident was further discussed with all technicians in the involved group at a regular team meeting. The veterinarian that suggested the antibiotic treatment underwent retraining stressing the importance of making sure that all substances administered to live animals are in the protocol, or if they are not, that the PI must request and have approved an amendment to the protocol to include the new substance prior to its administration. There were no adverse consequences associated with this treatment. The animals involved were supported by PHS funds.

The LSVC ACUC discussed this incident in full committee and determined that the corrective steps taken were appropriate. If you have further questions, please feel free to contact either of us or Drs. Janet Welter or Andrew Jefcoat.

Sincerely,

[REDACTED] (b) (6)

Ricki Colman, Ph.D.
Chair, LSVC ACUC

[REDACTED] (b) (6)

Nadine P. Connor, Ph.D.

Research Animal Resources Center

396 Enzyme Institute University of Wisconsin-Madison 1710 University Avenue Madison, Wisconsin 53726-4087
608/262-1238 Fax: 608/265-2698 Email: help@rarc.wisc.edu http://www.rarc.wisc.edu

Associate Vice Chancellor for Research Policy & Compliance
Institutional Official

xc: [REDACTED] (b) (6)

Janet Welter

[REDACTED] (b) (6)

AAALAC-I

Wolff, Axel (NIH/OD) [E]

From: OLAW Division of Compliance Oversight (NIH/OD)
Sent: Monday, January 10, 2022 7:35 AM
To: (b) (6)
Cc: OLAW Division of Compliance Oversight (NIH/OD)
Subject: RE: Incident Report from Nadine Connor @ UW-Madison

Thank you. We will send a response soon.
Axel Wolff

From: (b) (6)
Sent: Friday, January 7, 2022 3:39 PM
To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>
Cc: AAALAC International <accredit@AAALAC.org>; RICKI J COLMAN <ricolman@wisc.edu>; Nadine Connor <nadine.connor@wisc.edu>; (b) (6) Janet Welter <welter@rarc.wisc.edu>; (b) (6)
Subject: [EXTERNAL] Incident Report from Nadine Connor @ UW-Madison

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and are confident the content is safe.

Dr. Morse:

Please see the attached incident final report from Nadine Connor @ UW-Madison. Thanks!

(b) (6)



A3368-11 X

Initial Report of Noncompliance

By: BCM

Date: 12/22/2021

Time: 3:30

Person Reporting: [redacted] (b) (6)
Telephone #: [redacted] (b) (6)
Fax #:
Email:

Name of Institution: __Univ. of Wisconsin (Madison)_ WNPRC _____
Assurance number: __A3368_____

Did incident involve PHS funded activity? __yes__
Funding component: _____
Was funding component contacted (if necessary): _____

Two rhesus females received antibiotic treatment to prepare for model of vaginal *Niceria* infection. Treatment not in protocol.

Species involved: Macaque
Personnel involved:
Dates and times:
Animal deaths: no

Projected plan and schedule for correction/prevention (if known): _____

Protocol to be amended.

Projected submission to OLAW of final report from Institutional Official:

< 60 days

OFFICE USE ONLY
Case # _____